SEARCH

SEARCH BY CITATION

References

  • Behl C. (1999a) Alzheimer's disease and oxidative stress: implications␣for novel therapeutic approaches. Prog. Neurobiol. 57, 301323.
  • Behl C. (1999b) Vitamin E and other antioxidants in neuroprotection. Int. J. Vitam. Nutr. Res. 69, 213219.
  • Behl C. and Holsboer F. (1999) The female sex hormone estrogen as neuroprotectant. Trends Pharm. Sci. 20, 441444.
  • Behl C., Davis J. B., Lesley R. and Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817827.
  • Chen Y. and Buck J. (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J. Pharmacol. Exp. Ther. 293, 807812.
  • Chun H. S., Gibson G. E., DeGiorgio L. A., Zhang H., Kidd V. J. and Son J. H. (2001) Dopaminergic cell death induced by MPP (+), oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76, 10101021.
  • De Petrocellis L., Bisogno T., Davis J. B., Pertwee R. G. and Di Marzo V. (2000) Overlap between the ligand recognition of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483, 5256.
  • Di Marzo V., Melck D., Bisogno T. and De Petrocellis L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521528.
  • Hampson A. J. and Grimaldi M. (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13, 15291536.
  • Hampson A. J., Grimaldi M., Axelrod J. and Wink D. (1998) Cannabidiol and (-) Δ9-tetrahydrocannabinol are neuroprotective␣antioxidants. Proc. Natl. Acad. Sci. USA 95, 82688273.
  • Hillard C. J., Muthian S. and Kearn C. S. (1999) Effects of CB1 canna- binoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 459, 277281.
  • Hillard C. J., Nogueron M. I. and Porgilsson B. (2000) Differential effects of CB1 receptor activation on calcium responses in neurites and soma of cerebellar granule cells. 2000 Symposium on the Cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, p. 44.
  • Jan T. R. and Kaminski N. E. (2001) Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J. Leukoc. Biol. 69, 841849.
  • Jin K. L., Mao X. O., Goldsmith P. C. and Greenberg D. A. (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48, 257261.
  • Ledent C., Valverde O., Cossu G., Petitet F., Aubert J. F., Beslot F., Bohme G. A., Imperato A., Pedrazzini T., Roques B. P., Vassart G., Fratta W. and Parmentier M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401404.DOI: 10.1126/science.283.5400.401
  • Maher P. and Davis J. B. (1996) The role of monoamine metabolism in oxidative glutamate toxicity. J. Neurosci. 16, 63946401.
  • Markesbery W. R. and Carney J. M. (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol. 9, 133146.
  • Matsuda L. A. (1997) Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. 11, 143166.
  • Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 34, 561564.
  • Meschler J. P., Kraichely D. M., Wilken G. H. and Howlett A. C. (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR 141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB1 cannabinoid receptor. Biochem. Pharmacol. 60, 13151323.
  • Moosmann B. and Behl C. (1999) The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl. Acad. Sci. USA 96, 88678872.
  • Nagayama T., Sinor A. D., Simon R. P., Chen J., Graham S. H., Jin K. and Greenberg D. A. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 29872995.
  • Panikashvili D., Simenidour C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R. and Shohami E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527531.DOI: 10.1038/35097089
  • Pertwee R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129180.
  • Piomelli D., Giuffrida A., Calignano A. and Rodriguez de Fonseca F. (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21, 218224.
  • Sambrook J., Fritsch E. F. and Maniatis T., eds. (1989) Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
  • Shire D., Calandra B., Bouaboula M., Barth F., Rinaldi-Carmona M., Casellas P. and Ferrara P. (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 65, 627635.
  • Simonian N. A. and Coyle J. T. (1996) Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36, 83106.
  • Sinor A. D., Irvin S. M. and Greenberg D. A. (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157160.
  • Song Z. H. and Bonner T. I. (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN 55,212-2. Mol. Pharmacol. 49, 891896.
  • Valjent E., Pages C., Rogard M., Besson M. J., Maldonado R. and Caboche J. (2001) Delta9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 14, 342352.DOI: 10.1046/j.0953-816X.2001.01652.x
  • Zimmer A., Zimmer A. M., Hohmann A. G., Herkenham M. and Bonner T. I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 57805785.